About Venue

Welcome to PBCV – Clinical Trials Conference in Shanghai, China

Explore the future of clinical research and medical innovation with global leaders and pioneers in the heart of China.

Reasons to Host the PBCV – Clinical Trials Conference 2026 in China

• Growing Pharmaceutical Industry

  • China has emerged as a global powerhouse in clinical trials and pharmaceutical R&D, with substantial investments driving innovation and discovery. The nation is home to a rapidly expanding ecosystem of CROs, pharmaceutical companies, and biotech firms, making it an ideal hub for cutting-edge clinical research.

• Strong Government Support

  • The Chinese government has prioritized clinical research and pharmaceutical innovation as part of national strategies like “Healthy China 2030” and “Made in China 2026.” These initiatives foster a regulatory and economic environment that actively supports international conferences and collaborative research.

• Large Market Potential

  • With one of the largest healthcare markets globally, China presents immense opportunities for stakeholders in clinical trials. Hosting the conference in Shanghai enables attendees to explore collaborations, investments, and market entry strategies in this dynamic and expanding sector.

• World-Class Facilities

  • Shanghai boasts world-class convention centers, research institutions, and medical facilities. Its advanced infrastructure and hospitality options make it a prime location for high-impact international events like the PBCV – Clinical Trials Conference.

• Access to a Large Talent Pool

  • China is home to thousands of professionals in the clinical trials, biotechnology, and pharmaceutical fields. The conference provides an opportunity to connect with a deep bench of researchers, clinicians, and regulatory experts.

• Opportunities for Collaboration

  • China’s robust network of universities, research institutes, and hospitals facilitates domestic and international collaboration. Hosting the PBCV Conference would foster new partnerships between Chinese and global institutions in clinical research.

• Cultural and Economic Impact

  • Bringing the conference to China highlights the country’s growing leadership in clinical trials and medical innovation. It also promotes cultural exchange, international cooperation, and scientific diplomacy.

• Strategic Location

  • China’s central location in Asia makes Shanghai a gateway city, easily accessible from around the world. This strategic advantage ensures participation from a broad, diverse global audience.

• Innovative Research Environment

  • From genomics and precision medicine to novel drug development and vaccine trials, China is actively advancing clinical research. The conference would thrive in this environment of innovation and fast-paced development.

• Economic and Trade Opportunities

  • The event serves as a platform to explore emerging markets, showcase innovations, and foster trade in clinical research services, technologies, and products.

• Rapid Technological Advancements

  • China leads in integrating technology such as AI, big data, and mobile health into clinical trials. Delegates can gain insights into cutting-edge practices and technologies transforming the trial landscape.

• Growing Global Influence

  • As China plays an increasingly influential role in shaping global clinical trial standards and regulations, hosting the PBCV Conference aligns with the global direction of the industry.

• Established International Networks

  • China has forged strong international ties in clinical research and pharmaceuticals. Leveraging these networks enhances the conference’s reach, collaboration potential, and international visibility.

• Government and Private Sector Investment

  • Massive public and private investments support infrastructure, research, and events, making China a reliable host for large-scale, impactful conferences.

• Commitment to Sustainable Practices

  • With growing attention to green innovation and sustainable healthcare, China’s commitment aligns with global values. The conference can spotlight sustainable practices in clinical trial design and healthcare delivery.

• Diverse Research Focus Areas

  • From oncology and neurology to infectious disease and regenerative medicine, China’s breadth of clinical research can enrich the conference program and draw interdisciplinary participation.

China’s leadership in clinical research, world-class infrastructure, and collaborative ecosystem make it an exceptional location for the PBCV – Clinical Trials Conference 2026. By choosing Shanghai as the host city, organizers can harness regional advantages to create a forward-thinking, globally impactful event that fosters innovation, partnership, and scientific excellence in clinical trials.